# Your choices depend on the sore joint *Options for Joint Soreness — Regenerative Medicine Gilbert* > Regenerative medicine Gilbert choices include home care, medicine, orthobiologics such as blood-based shots, and surgery. ## Exercise that doesn't worsen tomorrow is a sound start Regular, gentle exercise supports the muscles around your joint. It may ease stiffness and help you stay steady. The right amount still lets you move the next day. More isn't useful when the soreness keeps rising. Warmth, cold, a brace, or a cane may make daily tasks easier. Your doctor can say whether pain medicine suits your health. They'll still matter if you later consider a shot or surgery. How you feel the next morning helps set the amount. ## Short sessions are often easier on a sore joint A short walk or gentle strength work may be enough at first. Use a smaller range when a motion sharply raises the ache. When tomorrow brings more soreness, shorten the next session. Don't stop moving unless a doctor tells you to rest. Long rest can weaken the muscles and add stiffness. A physical therapist can adjust the exercises when safety isn't clear. Comfort the next day is a useful check. If sleep, walking, or dressing keeps getting harder, see a doctor. The exam can uncover another cause and guide new exercises. ## Each choice may help a different joint problem Medicine may reduce soreness for a while. Surgery can repair or replace joint parts when damage calls for it. Before knee or hip surgery, a doctor may compare exercise, medicine, a brace, and a blood-based shot. The best choice for you depends on the exam and X-ray. To prepare PRP, clinic staff draw blood and spin it before giving the shot. Orthobiologics means joint shots made from blood or other body tissue. QC Kinetix may offer these non-surgical regenerative treatments for joint soreness after an exam. Less aching can happen without a change on the X-ray. A blood-based shot isn't the same as rebuilding the joint. Joint preservation means care meant to keep the joint you have useful. It may include exercise, sensible activity changes, medicine, or a shot. Surgery can still be the right choice when those measures aren't enough. ## Price and time afterward belong in the decision Ask the clinic for the full written price and any limits afterward. Insurance won't pay for every choice. Return visits and the drive to Chandler also take time. Those details help you compare care without rushing. Ask how long pain relief may last and what happens if it doesn't. Nobody can know your result before treatment. The clinic's answer needs to say that plainly. Care you can choose may wait until the cause is clearer. Sudden swelling, fever, a fall, or lost strength needs medical care first. Those warning signs matter more than a planned shot. ## Sources 1. OARSI 2019 designates arthritis education plus structured land-based exercise (with or without dietary weight management) as CORE treatments for knee OA and strongly recommends topical NSAIDs (Level 1A), while strongly recommending AGAINST oral and transdermal opioids (Level 5). The treatments with the strongest evidence in this condition remain the least dramatic ones. Bannuru RR, et al. — [OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis.](https://pubmed.ncbi.nlm.nih.gov/31278997/). *Osteoarthritis and cartilage*, 2019. DOI: 10.1016/j.joca.2019.06.011. 2. The Cochrane review of exercise for knee osteoarthritis found high-quality evidence that land-based therapeutic exercise provides short-term benefit in pain and physical function, sustained for at least 2-6 months after the programme ends, with mild transient soreness the only reported adverse effect across 45 trials. It is the best-evidenced treatment for this condition and it costs nothing per injection. Fransen M, et al. — [Exercise for osteoarthritis of the knee.](https://pubmed.ncbi.nlm.nih.gov/25569281/). *The Cochrane database of systematic reviews*, 2015. DOI: 10.1002/14651858.CD004376.pub3. 3. In a 2-year RCT, intra-articular triamcinolone given every 12 weeks for knee OA produced significantly GREATER cartilage volume loss than saline, with no significant pain benefit. The most widely used joint injection in medicine is itself associated with structural harm on repeat dosing - relevant context when a clinic frames a biologic as 'the alternative to steroid shots'. McAlindon TE, et al. — [Effect of Intra-articular Triamcinolone vs Saline on Knee Cartilage Volume and Pain in Patients With Knee Osteoarthritis: A Randomized Clinical Trial.](https://pubmed.ncbi.nlm.nih.gov/28510679/). *JAMA*, 2017. DOI: 10.1001/jama.2017.5283. 4. The RESTORE trial - a participant-, injector- and assessor-blinded RCT of 288 adults aged 50+ with symptomatic medial knee OA (Kellgren-Lawrence 2-3) - compared three weekly intra-articular PRP injections against saline placebo, with co-primary endpoints of 12-month knee pain and medial tibial cartilage volume on MRI. PRP did not beat placebo on either. It is the single best-designed test of the specific claim that PRP changes joint structure, and it was negative. Bennell KL, et al. — [Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.](https://pubmed.ncbi.nlm.nih.gov/34812863/). *JAMA*, 2021. DOI: 10.1001/jama.2021.19415. 5. A four-arm, multicentre, single-blind phase 2/3 randomized trial of 480 knee OA patients (KL II-IV) compared autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction and allogeneic umbilical-cord-tissue mesenchymal stromal cells against a corticosteroid injection control. At 12 months NONE of the three orthobiologic injections was superior to another, or to the corticosteroid control, and none of the four groups showed a significant change in MRI osteoarthritis score from baseline. No procedure-related serious adverse events occurred. Mautner K, et al. — [Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.](https://pubmed.ncbi.nlm.nih.gov/37919438/). *Nature medicine*, 2023. DOI: 10.1038/s41591-023-02632-w. 6. A 2026 systematic review and meta-analysis of 28 randomized trials of intra-articular mesenchymal stem cell-based therapies in knee OA found significant improvements in several pain and function measures (delta-VAS MD -1.67; KOOS pain MD 15.37) but NO significant difference in WOMAC, KOOS quality of life or the Lequesne index, and MRI-based WORMS scores were non-significant - indicating no consistent structural benefit. Its own conclusion: these therapies serve a primarily SYMPTOM-modifying rather than STRUCTURE-modifying role, with higher frequencies of local reactions to weigh against the symptomatic benefit. Awad G, et al. — [Efficacy and safety of intra-articular mesenchymal stem cell-based therapies in knee osteoarthritis: A systematic review and meta-analysis of randomized controlled trials.](https://pubmed.ncbi.nlm.nih.gov/41863718/). *Clinical rheumatology*, 2026. DOI: 10.1007/s10067-026-08042-w. 7. FORWARD, the longest disease-modifying osteoarthritis drug trial reported to date, gave intra-articular sprifermin (a recombinant FGF-18) or placebo to knee OA patients and followed 378 of them for 5 years. Sprifermin produced a significant, sustained dose-response INCREASE in total femorotibial cartilage thickness versus placebo - and WOMAC pain improved about 50% from baseline in ALL groups, including placebo. It is the cleanest demonstration in the literature that adding measurable cartilage and relieving pain are two different results, and that one does not deliver the other. Eckstein F, et al. — [Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study.](https://pubmed.ncbi.nlm.nih.gov/33962962/). *Annals of the rheumatic diseases*, 2021. DOI: 10.1136/annrheumdis-2020-219181. 8. A GRADE-rated systematic review and meta-analysis of 16 randomized trials (807 participants) found that MSC therapy for chronic knee OA pain PROBABLY RESULTS IN LITTLE TO NO DIFFERENCE in pain relief at 3-6 months (WMD -0.74 cm on a 10 cm VAS against a minimally important difference of 1.5 cm) or physical functioning (WMD 2.23 on the SF-36 100-point subscale against a 10-point MID), both moderate certainty; at 12 months pain was again probably little-to-no-different (WMD -0.73 cm). The measured effect is real but sits BELOW the threshold at which a patient would notice it. Sadeghirad B, et al. — [Mesenchymal stem cells for chronic knee pain secondary to osteoarthritis: A systematic review and meta-analysis of randomized trials.](https://pubmed.ncbi.nlm.nih.gov/38777213/). *Osteoarthritis and cartilage*, 2024. DOI: 10.1016/j.joca.2024.04.021. 9. MACI (autologous cultured chondrocytes on a porcine collagen membrane, Vericel; STN BL 125603) IS an FDA-LICENSED cell therapy - and its approved indication is narrow and specific: repair of symptomatic, single or multiple FULL-THICKNESS cartilage defects OF THE KNEE, with or without bone involvement, in adults. It is not approved for osteoarthritis. The existence of one licensed cartilage cell therapy for focal defects is the sharpest available way to show what a licensed 'regeneration' product actually looks like, and how far it is from an injection for a worn joint. US Food and Drug Administration, Center for Biologics Evaluation and Research — [MACI (autologous cultured chondrocytes on porcine collagen membrane)](https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/maci-autologous-cultured-chondrocytes-porcine-collagen-membrane). *FDA*, 2024. 10. FDA's public list of licensed cellular and gene therapy products is the checkable answer to 'is this FDA-approved?'. A product not on that list, and not being administered under an active IND, is not an approved therapy however it is described in a brochure. For orthopedics the list is short and its cartilage entry is MACI, indicated for focal full-thickness knee defects. US Food and Drug Administration, Center for Biologics Evaluation and Research — [Approved Cellular and Gene Therapy Products](https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products). *FDA*, 2026. ## The visit should leave you with clear answers A visit can cover your joint, the tasks getting harder, and possible care. Ask how much pain relief may occur, the full cost, recovery time, and other choices. Schedule a free consultation: --- Help for soreness and your next visit. Read about causes of your soreness, useful home care, blood-based shots, and the QC Kinetix office near Gilbert. Plain help for Gilbert residents with a sore joint. This Gilbert regenerative-medicine site is operated by the owners of the QC Kinetix Phoenix-area clinics. © 2026 Gilbert Regeneration Field Guide. Educational information only; not a substitute for personal medical advice.